Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:43:00.980Z.
Calculation as of: 2026-10-06T19:43:00.980Z.
Quote observation: 2026-10-06T19:40:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 673a23962afa1f964289f2c5c8e96f6ae4ccf5481b64718d91ae2e5553a82c87
PE RATIO
N/A
Market Cap
$170.69M
PE Ratio
N/A
TTM Avg
11.57
3Y Avg
11.57
5Y Avg
11.57
Market Cap
$169.32M
PE Ratio
N/A
TTM Avg
22.05
3Y Avg
43.38
5Y Avg
28.58
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProQR Therapeutics N.V. (PRQR) | $174.81M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $175.90M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $170.69M | N/A | 11.57 | 11.57 | 11.57 |
| Journey Medical Corporation (DERM)vs › | $171.32M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.87M | 1.07 | 2.35 | 8.36 | 8.36 |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.32M | N/A | 22.05 | 43.38 | 28.58 |
| MediWound Ltd. (MDWD)vs › | $168.79M | N/A | 7.76 | 7.76 | 7.76 |
| Compass Therapeutics, Inc. (CMPX)vs › | $180.99M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $182.43M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $167.81M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
